WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Web Hosting Web Host Industry Sunday, December 4, 2022 
Add Press Release News | News Feeds Feeds | Email This News Email


Fragment-Based Drug Discovery -- Hitting Targets Using the Right Chemistry and Expertise Alliances, Upcoming Webinar Hosted by Xtalks
Saturday, October 1, 2022

In this free webinar, learn about an alliance of experts in biophysics, crystallography and medicinal chemistry. The featured speakers will discuss innovations from fragment identification to lead optimization stage to identify preclinical drug candidates. Attendees will learn about the use of covalent fragment screening to target cysteine and find quality leads. The speakers will also discuss how covalent binding allows targeting traditionally challenging targets.

TORONTO, Sept. 26, 2022 /PRNewswire-PRWeb/ -- Fragment Based Drug Discovery (FBDD) has become of increasing importance and interest in the past decade for hit finding and optimization. FBDD led to approved therapeutics and numerous drug candidates. It has empowered the industry to address targets that had previously been deemed "undruggable".

FBDD uses the advantages of biophysical, biostructural and biochemical methods for the detection of low molecular weight molecules, so-called "fragments", that bind to a target. FBDD exhibits several advantages over high-throughput screening campaigns in terms of cost, chemical diversity, and broader sampling for potential follow-up compounds.

Numerous case studies of covalent and non-covalent screening fragment strategies have led to successful applications in druggability assessment of proteins. In this talk, experts in the field of FBDD will present case studies and potential of a spectrum of cutting-edge strategies for a successful hit identification and optimization campaigns.

In addition, Dr. Nir London (Weizmann Institute of Science, Israel) will present how electrophilic fragment screening can accelerate the discovery of a new generation of covalent probes for challenging targets. Here he will describe application of this method for the discovery of the first in-vivo active chemical probe for the proline isomerase Pin1, as well as against the SARS-CoV-2 main protease.

Join this webinar to learn how fragment-based drug discovery solutions --such as DRIVE-SM -- enable the identification, characterization, design and optimization of fragments into a preclinical drug candidate.

Join Dr. Thomas Schubert, Managing Director, 2bind; Dr. Serghei Glinca, Founder & CEO, CrystalsFirst; Dr. Nir London, President of the Med. Chem. Section of the Israel Chemical Society, Weizmann Institute; and Dr. Yann Lamotte, Chemistry Team Manager, Oncodesign, for the live webinar on Thursday, October 13, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Fragment-Based Drug Discovery -- Hitting Targets Using the Right Chemistry and Expertise Alliances.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com

SOURCE Xtalks



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav The Top Web Design Companies In December, According To DesignRush | Dec 3, 2022
Nav ACL Digital Acquires AFour Technologies, a Next-Generation 360° Software Product Engineering Company to Expand and Scale its Product Engineering & Digital Capabilities | Dec 3, 2022
Nav Bolt Data and Salesforce Share 'Honest Conversations on Preparing for Salesforce Transformations' in Upcoming Webinar | Dec 3, 2022
Nav ActionIQ Announces Support for AWS for Advertising and Marketing Initiative | Dec 3, 2022
Nav Fingerpaint Group Launches Edgy Campaign to Help Men See Therapy as a Strength, Not a Weakness | Dec 3, 2022
Nav Mode Welcomes Florian Schouten as Vice President, Product & Design | Dec 3, 2022
Nav New Survey Study Uncovers What Company Holiday Event Planning Looks Like in 2022 | Dec 3, 2022
Nav Healthcare CRM Global Market Report 2022: Ukraine-Russia War Impact | Dec 3, 2022
Nav Outlook on the Automotive HUD Global Market to 2028 - Players Include Robert Bosch, Panasonic, Continental and Nippon Seiki | Dec 3, 2022
Nav KBR to Upgrade, Integrate New Technology for U.S. Navy Aircraft Through $69.2M Contract Win | Dec 3, 2022
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News